Apollomics (Nasdaq: APLM) entered into definitive subscription agreements for a $10.0 million private placement with accredited investors. The transaction is expected to close on or about August 14, 2026, subject to customary conditions.The private placement includes cash subscriptions for 533,334 Class A shares at $15.00 per share, for gross cash proceeds of about $8.0 million, and the automatic conversion of a $2.0 million unsecured convertible promissory note held by CEO Hung-Wen (Howard) Chen into 166,667 Class A shares at $12.00 per share. Certain executive officers and directors or their affiliates are participating in the cash portion. No placement agents or underwriters are involved, and no finder's fees or commissions are payable. The shares will be issued as unregistered, restricted securities under exemptions including Section 4(a)(2) and Rule 506 of Regulation D.

Reported Friday, Jul 17 - 9:52am EDT (TheFly subscription required to read more.)

Reported Friday, Jul 17 - 9:47am EDT (TheFly subscription required to read more.)

Nasdaq staff notified Apollomics on July 8 that its market value of listed securities met the $35M Rule 5550(b)(2) minimum for 10 straight days, closing the matter.

Reported Monday, Jul 13 - 9:18am EDT (TheFly subscription required to read more.)

Apollomics raised $2.0M in a CEO-provided bridge loan reported Apr 1, 2026; terms were not disclosed and the facility likely covers only short-term runway.

Plus, news about Spyre Therapeutics, Candel Therapeutics, Boehringer Ingelheim, Quantro Therapeutics, Clover, EVerZom and Apollomics.